PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Asthma (Airomir Autohaler (salbutamol MDI) - Asthma)

Records returned : 11 (on 22 Dec 2024 at 18:39:51). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
03.01.01
07.01.03
Salbutamol
Asthma
Green
Formulations :
  • Nebules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
03.03.02
Montelukast
Asthma
Green
Formulations :
  • Chewable tablets
  • Sachets (granules)
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions
03.01.01
Terbutaline sulphate
Asthma
Blue
Formulations :
  • Nebules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Primary Care may prescribe on recommendation from the Respiratory Care Team who will ensure that patients have had suitable training and trial of equipment to ensure safe use.
01.05.02
03.02.00
05.03.06
06.03.02
Budesonide
Asthma
Blue
Formulations :
  • Nebules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Asthma prophylaxis. Primary Care may prescribe on recommendation from the Respiratory Care Team who will ensure that patients have had suitable training and trial of equipment to ensure safe use.
Dupilumab
Asthma
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Specialised commissioned services only.
03.01.01
07.01.03
Salbutamol
Asthma
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Unlicensed use in under 12 years of age.
03.01.01
Terbutaline sulphate
Asthma
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Severe acute asthma
Sereflo Ciphaler (Salmeterol / Fluticasone) DPI
Asthma
N/A
Formulations :
  • Inhaler (dry powder)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD2
Campona Airmaster (Salmeterol / Fluticasone) DPI
Asthma
N/A
Formulations :
  • Inhaler (dry powder)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD2
03.01.01
07.01.03
Salbutamol
Asthma
Non Formulary
Formulations :
  • Modified release tablets
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
03.01.03
Theophylline
Asthma
See narrative
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Place in therapy under review. Therapeutic drug monitoring required. Not recommended for primary care initiation without specialist advice.
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More